Our solution is a state of the art steerable drilling technology and a novel implant featuring advanced precision to ensure higher accuracy in complex orthopedics and neurosurgical procedures and improve patient outcomes.
Infants born extremely prematurely present significant clinical and population health challenges. Advances in clinical vital sign monitoring can drive improvements in survival and long-term outcomes in this vulnerable population. Our company develops a multifunctional feeding tube that simultaneously provides vital sign monitoring by sensors embedded in a feeding tube indwelling inside the patient's esophagus instead of using irritant skin-mounted sensors. Trinity tube is the next-generation solution for neonatal vital sign monitoring.
We help dentists and medical professionals sterilize equipment in a few minutes instead of an hour using special light instead of wasting water. An average dentist saves $100,000 and 2 million gallons of water each year.
DASI Simulations is a medical technology company that uses artificial intelligence (AI) and computational modeling to create personalized 3D simulations for heart valve procedures, particularly Transcatheter Aortic Valve Replacement (TAVR).
OrthoPreserve is developing a minimally invasive meniscus implant to relieve pain, restore mobility, and reduce the risk of knee joint arthritis for patients.
Atlas Endoscopy is revolutionizing gastrointestinal diagnostics with a groundbreaking robotic system that performs painless, unsedated colonoscopies using magnetic guidance and an ultra-flexible endoscope. Our innovative technology eliminates the need for sedation, decontamination, and lengthy recovery times, allowing patients to complete procedures in just 30 minutes. Designed for both upper and lower GI applications, our solution enhances accessibility, reduces healthcare costs, and increases capacity by enabling satellite center,out-of-hospital use in clinics and GP surgeries worldwide
Orion Therapeutics is a delivery platform-enabled RNA therapeutics company. We pair a proprietary lipid nanoparticle GENESYS™ delivery platform that entirely excludes ionizable cationic lipids with a vascular RNA therapy pipeline. Our safe, versatile, scalable, and targeted delivery platform can be leveraged across a broad range of disease applications to advance RNA therapies to market internally and in partnership.
Annate Bitherapeutics is developing a therapeutic platform that utilizes ApoL1, a naturally occurring component of the innate immune system. It is guided by our proprietary bispecific antibodies to become selectively lethal to cancer cells. This innovative mechanism complements existing therapies, with strong efficacy in multiple myeloma and promising preclinical results in pancreatic cancer models, demonstrating the platform’s broad potential across multiple tumor types.
Azome is developing first in class drugs to revolutionize the treatment of severe inflammatory diseases and injuries including bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), exacerbations in idiopathic lung fibrosis (ILF), acute lung injury, acute kidney injury, and sepsis for which there are currently no preventative and a limited set of therapeutic options.
Empath Biosciences has developed a revolutionary drug discovery platform that overcomes barriers to scaling therapeutics from nature’s biodiversity, de-risks each step of the development process, and efficiently yields novel therapeutics. The lead, proof-of-principle chemical series is currently in IND-enabling studies and scheduled to be in the clinic in 2026.
